A New Drug Application has been submitted in the usa, where priority overview of the compound has been requested. Data from clinical studies, like the phase III AFFIRM study, have demonstrated that enzalutamide significantly improves overall survival whilst providing a favourable tolerability profile for sufferers, said Professor Johann de Bono, M.D., MSc, Ph.D., FRCP, Honorary Consultant in Medical Oncology, Professor in Experimental Malignancy Medicine, The Institute of Cancer Study, The Royal Marsden Medical center and co-principal investigator of the AFFIRM research. This is vital for patients at this late stage of their disease and the submission of enzalutamide represents an important step towards making this promising treatment available to guys with advanced prostate cancer across Europe.Both his eyes got become blind when he was in his 40s, he was still in a position to work his newspaper empire regardless however.
Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010 Array BioPharma Inc. today reported economic results for the 3rd quarter of fiscal 2010.4 million for the third quarter of fiscal 2010, in comparison to revenue of $6.0 million for the same period in fiscal 2009. Array spent $17.7 million for proprietary research and development during the quarter to advance its wholly-owned medications in clinical advancement and discovery applications. This comes even close to $20.0 million spent for research and advancement during the third quarter of fiscal 2009. Array’s net loss improved to $15.2 million, or per talk about, for the 3rd quarter, in comparison to a net lack of $29.6 million, or per share, for the third quarter in fiscal 2009.